In Brief: Former Bard execs sentencing
This article was originally published in The Gray Sheet
Executive Summary
Former Bard execs sentencing: Judge Joseph Tauro, U.S. District Court, Boston, schedules Aug. 8 sentencing of three ex-Bard executives convicted in August 1995 of conspiring to defraud FDA ("The Gray Sheet" Aug. 28, 1995, p. 2). The former execs convicted are: Bard group exec VP David Prigmore; John Cvinar, former President of Bard's USCI angioplasty catheter division; and Lee Leichter, former director of regulatory affairs and quality assurance for USCI. Former Bard CEO, George Maloney, and Kenneth Thurston, former director of regulatory affairs for USCI, were acquitted. Charges facing Janice Piasecki, a former supervisor in the regulatory affairs department, were dropped. The three defendants found guilty each face up to five years imprisonment and a fine of $250,000...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.